LY-266097, a selective 5-HT2BR antagonist, effectively reduces tactile hypersensitivity and demonstrates potential therapeutic effects in alleviating pain caused by nerve injury. Additionally, it decreases the upregulation of 5-HT2B receptors in the dorsal root ganglia and spinal cord following nerve damage. Research indicates that LY-266097 may play a potential role in the development of neuropathic pain pathways.